EA202092926A3 - Лиофилизированные составы, содержащие фактор ix - Google Patents

Лиофилизированные составы, содержащие фактор ix

Info

Publication number
EA202092926A3
EA202092926A3 EA202092926A EA202092926A EA202092926A3 EA 202092926 A3 EA202092926 A3 EA 202092926A3 EA 202092926 A EA202092926 A EA 202092926A EA 202092926 A EA202092926 A EA 202092926A EA 202092926 A3 EA202092926 A3 EA 202092926A3
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions containing
lyophilized compositions
containing factor
factor
lyophilized
Prior art date
Application number
EA202092926A
Other languages
English (en)
Other versions
EA202092926A2 (ru
Inventor
Брайан М. Тоум
Чери Паркхурст-Ланг
Брэндон В. Левейлл
Original Assignee
Биовератив Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196282&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202092926(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Биовератив Терапьютикс Инк. filed Critical Биовератив Терапьютикс Инк.
Publication of EA202092926A2 publication Critical patent/EA202092926A2/ru
Publication of EA202092926A3 publication Critical patent/EA202092926A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mechanical Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA202092926A 2014-03-24 2015-03-24 Лиофилизированные составы, содержащие фактор ix EA202092926A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969801P 2014-03-24 2014-03-24

Publications (2)

Publication Number Publication Date
EA202092926A2 EA202092926A2 (ru) 2021-07-30
EA202092926A3 true EA202092926A3 (ru) 2021-10-29

Family

ID=54196282

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691807A EA038573B1 (ru) 2014-03-24 2015-03-24 Лиофилизированный состав, содержащий фактор ix, для предупреждения приступов кровотечения
EA202092926A EA202092926A3 (ru) 2014-03-24 2015-03-24 Лиофилизированные составы, содержащие фактор ix

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201691807A EA038573B1 (ru) 2014-03-24 2015-03-24 Лиофилизированный состав, содержащий фактор ix, для предупреждения приступов кровотечения

Country Status (17)

Country Link
US (2) US10772942B2 (ru)
EP (1) EP3123090A4 (ru)
JP (4) JP7058940B2 (ru)
KR (1) KR102385372B1 (ru)
AR (1) AR099838A1 (ru)
AU (3) AU2015236340B2 (ru)
BR (1) BR112016021777A2 (ru)
CA (1) CA2943034C (ru)
CL (1) CL2016002386A1 (ru)
EA (2) EA038573B1 (ru)
IL (3) IL247869B (ru)
MA (1) MA39779A (ru)
MX (2) MX2016012447A (ru)
PH (1) PH12016501877A1 (ru)
SG (3) SG11201607642RA (ru)
TW (1) TWI700101B (ru)
WO (1) WO2015148444A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968498A4 (en) * 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
KR102385372B1 (ko) * 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
US11400051B2 (en) * 2017-07-11 2022-08-02 Universal Stabilization Technologies, Inc. Method for preserving biopharmaceuticals
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
US20210395325A1 (en) * 2020-05-11 2021-12-23 Alkermes Pharma Ireland Limited Il-2 fusion polypeptide compositions and methods of making and using the same

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
DK0461200T3 (da) 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
IN184589B (ru) * 1996-10-16 2000-09-09 Alza Corp
EP1219298A4 (en) * 1999-09-17 2003-06-11 Takeda Chemical Industries Ltd PROCESS FOR PRODUCING PROTEIN POWDER
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
CA2457429A1 (en) 2001-09-04 2003-03-13 Francis J. Carr Modified factor ix
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
AU2005225000A1 (en) 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
LT3130601T (lt) 2004-11-12 2020-09-10 Bayer Healthcare Llc Į vietą nukreipta fviii modifikacija
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007014073A2 (en) * 2005-07-22 2007-02-01 Amgen Inc. Concentrated protein lyophilates, methods, and uses
CA2625998C (en) * 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
KR20110128957A (ko) * 2005-11-01 2011-11-30 와이어쓰 엘엘씨 약물 재구성 또는 희석을 위한 염화나트륨 용액
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
MX2008012748A (es) 2006-04-04 2009-01-07 Shire Pharmaceuticals Ireland Un proceso para la concentracion de un polipeptido.
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US8015841B2 (en) * 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
CN104004739A (zh) 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ix变体
AU2008342260B2 (en) 2007-12-27 2013-10-17 Baxter Healthcare S.A. Chemically modified Factor IX
RU2010146387A (ru) 2008-04-16 2012-05-27 БАЙЕР ХЕЛСКЕР ЛЛСи (US) Модифицированные полипептиды фактора ix и их применение
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
US9884019B2 (en) 2008-08-05 2018-02-06 Wyeth Llc Lyophilization above collapse
GB2479069B (en) 2008-09-24 2012-07-25 Stabilitech Ltd Method for preserving polypeptides using a sugar and polyethyleneimine
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
SG188662A1 (en) 2010-09-30 2013-05-31 Toyama Chemical Co Ltd Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
CA2827033A1 (en) 2011-02-09 2012-08-16 Glaxosmithkline Llc Lyophilized formulations
AU2013270682A1 (en) * 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
WO2014052490A1 (en) * 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
EP2968498A4 (en) * 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
KR102385372B1 (ko) * 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형

Also Published As

Publication number Publication date
IL281197A (en) 2021-04-29
MX2021012939A (es) 2021-11-25
CA2943034C (en) 2022-06-14
SG11201607642RA (en) 2016-10-28
PH12016501877A1 (en) 2016-12-19
KR20160137577A (ko) 2016-11-30
MX2016012447A (es) 2017-01-06
NZ724351A (en) 2023-10-27
SG10201808249VA (en) 2018-10-30
AU2020202863A1 (en) 2020-05-21
US20170173122A1 (en) 2017-06-22
US10772942B2 (en) 2020-09-15
US20210069307A1 (en) 2021-03-11
JP2020063313A (ja) 2020-04-23
EA201691807A1 (ru) 2017-03-31
BR112016021777A2 (pt) 2017-10-03
IL247869B (en) 2020-02-27
JP2017510585A (ja) 2017-04-13
IL272257B (en) 2021-03-25
AU2020202863B2 (en) 2022-09-01
EA038573B1 (ru) 2021-09-16
MA39779A (fr) 2017-02-01
IL272257A (en) 2020-02-27
KR102385372B1 (ko) 2022-04-11
AR099838A1 (es) 2016-08-24
EA202092926A2 (ru) 2021-07-30
JP2024053015A (ja) 2024-04-12
CL2016002386A1 (es) 2017-06-23
IL281197B (en) 2022-06-01
JP7058940B2 (ja) 2022-04-25
AU2015236340A1 (en) 2016-09-29
AU2015236340B2 (en) 2020-02-06
WO2015148444A1 (en) 2015-10-01
EP3123090A1 (en) 2017-02-01
TWI700101B (zh) 2020-08-01
IL247869A0 (en) 2016-11-30
JP2022044689A (ja) 2022-03-17
SG10201913735SA (en) 2020-03-30
TW201605492A (zh) 2016-02-16
AU2022215218A1 (en) 2022-09-01
EP3123090A4 (en) 2017-12-13
CA2943034A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
DK3361870T3 (da) Fungicidsammensætninger
DK3536380T3 (da) Hurtigtvirkende insulinsammensætninger
DK3233108T3 (da) Hurtigtvirkende insulinsammensætninger
DK3406697T3 (da) Detergentsammensætning
BR112016023628A2 (pt) composições farmacêuticas.
DK3542812T3 (da) Glycopeptidsammensætninger
DK3139769T3 (da) Næringsrige sammensætninger
DK3040326T3 (da) Haloolefin-baseret sammensætning
DK3334726T3 (da) Plinabulinsammensætninger
DK3226842T3 (da) Anticancersammensætninger
DK3226843T3 (da) Anticancersammensætninger
FR3024363B1 (fr) Composition thermogelifiable
DK3250182T3 (da) Dispergible sammensætninger
CL2017000639A1 (es) Composición
DK3331498T3 (da) Nasalsammensætning
DK3397352T3 (da) Antiperspirantsammensætninger
SI3220893T1 (sl) Sestavek na osnovi COQ10
DK3397734T3 (da) Brændstofsammensætning
DK3316857T3 (da) Multifasiske sammensætninger
EA202092926A3 (ru) Лиофилизированные составы, содержащие фактор ix
DK3393254T3 (da) Sammensætning
DK3200827T3 (da) Sammensætninger
DK3337322T3 (da) Fungicidsammensætninger
DK3288536T3 (da) Sammensætninger omfattende anakinra
BR112017016240A2 (pt) composição